true 0001560293 0001560293 2023-12-21 2023-12-21 0001560293 TNON:CommonStockParValue0.001PerShareMember 2023-12-21 2023-12-21 0001560293 TNON:WarrantsMember 2023-12-21 2023-12-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K/A

 

CURRENT REPORT

(Amendment No. 2)

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): 

December 21, 2023

 

TENON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41364   45-5574718
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

104 Cooper Court    
Los Gatos, CA   95032
(Address of principal executive offices)   (Zip Code)

 

(408) 649-5760

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   TNON   The Nasdaq Stock Market LLC
Warrants   TNONW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Amendment No. 2 (“Amendment No. 2”) to the Current Report on Form 8-K is being filed as the second amendment to the Current Report on Form 8-K (the “Amended Form 8-K”) filed by Tenon Medical, Inc. (the “Company”) on December 26, 2023 as amended by Amendment No. 1 thereto filed on January 11, 2023. The sole purpose of this Amendment No. 2 is to supplement the disclosure in the Amended Form 8-K with details of the special meeting of the Company’s stockholders held on January 30, 2024 that was held after the adjournment of the special meetings of the Company’s stockholders held on December 21, 2023 and January 8, 2024. This Amendment No. 2 does not otherwise change or update the disclosure set forth in the Amended Form 8-K and does not otherwise reflect events after the Amended Form 8-K.

 

1

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

The Company convened its virtual Special Stockholders Meeting (the “Meeting”) on January 30, 2024 at 1:30 p.m. Pacific Time that was a continuation of the adjourned special meeting of the Company’s stockholders that was held on January 8, 2024, which was the continuation of the adjourned special meeting of the Company’s stockholders that was held on December 21, 2023. A quorum was present for the Meeting.

 

At the Meeting, Proposal 2 was submitted to the stockholders for approval as set forth in the definitive Proxy Statement as filed with the Securities and Exchange Commission on November 22, 2023. As of the record date, November 9, 2023, a total of 2,471,046 shares of common stock of the Company (“Common Stock”) were issued and outstanding and entitled to vote. The Common Stock constitutes all of the securities of the Company entitled to vote at the Meeting. The holders of record of 1,777,436 shares of Common Stock were present in person or represented by proxy at said meeting. Such amounts represented approximately 71.93% of the Common Stock entitled to vote at such meeting.

 

At the Meeting, the stockholders approved Proposal 2. The votes on Proposal 2 were cast as set forth below:

 

Proposal No. 2 – To consider and vote on a proposal to approve an amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to expressly vest in the Board of Directors of the Company (the “Board”) the authority to issue the preferred stock with powers, designations, preferences and relative, participating, optional or other rights, if any, or the qualifications, limitations or restrictions thereof as the Board;

 

For   Against   Abstain
1,243,383   73,920   21,473

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 31, 2024 TENON MEDICAL, INC.
   
   
  By: /s/ Steven M. Foster
  Name: Steven M. Foster
  Title: Chief Executive Officer and President

 

3

 

v3.24.0.1
Cover
Dec. 21, 2023
Document Type 8-K/A
Amendment Flag true
Amendment Description This Amendment No. 2 (“Amendment No. 2”) to the Current Report on Form 8-K is being filed as the second amendment to the Current Report on Form 8-K (the “Amended Form 8-K”) filed by Tenon Medical, Inc. (the “Company”) on December 26, 2023 as amended by Amendment No. 1 thereto filed on January 11, 2023. The sole purpose of this Amendment No. 2 is to supplement the disclosure in the Amended Form 8-K with details of the special meeting of the Company’s stockholders held on January 30, 2024 that was held after the adjournment of the special meetings of the Company’s stockholders held on December 21, 2023 and January 8, 2024. This Amendment No. 2 does not otherwise change or update the disclosure set forth in the Amended Form 8-K and does not otherwise reflect events after the Amended Form 8-K.
Document Period End Date Dec. 21, 2023
Entity File Number 001-41364
Entity Registrant Name TENON MEDICAL, INC.
Entity Central Index Key 0001560293
Entity Tax Identification Number 45-5574718
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 104 Cooper Court
Entity Address, City or Town Los Gatos
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95032
City Area Code 408
Local Phone Number 649-5760
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock, par value $0.001 per share  
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TNON
Security Exchange Name NASDAQ
Warrants  
Title of 12(b) Security Warrants
Trading Symbol TNONW
Security Exchange Name NASDAQ
Tenon Medical (NASDAQ:TNON)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Tenon Medical Charts.
Tenon Medical (NASDAQ:TNON)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Tenon Medical Charts.